Program

Wednesday, November 20

11.00 Welcome

<table>
<thead>
<tr>
<th>Drug Development: Antibiotics and Resistances</th>
<th>Chair: Ute Hentschel</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>11.15</strong> Thomas Henkel</td>
<td></td>
</tr>
<tr>
<td>Strategies for molecular prevention of bacterial and fungal infections - represent Glycolipids a new option?</td>
<td></td>
</tr>
<tr>
<td><strong>11.50</strong> Peter Hammann</td>
<td></td>
</tr>
<tr>
<td>Status and Perspectives of Antibiotics: Special focus on Natural Products</td>
<td></td>
</tr>
<tr>
<td><strong>12.25</strong> Robert Beardmore</td>
<td></td>
</tr>
<tr>
<td>Mathematical and Laboratory Models of Antibiotic Use: predicting bacterial clearance at sub-lethal dosages in the presence of chromosomal multidrug resistance adaptation</td>
<td></td>
</tr>
</tbody>
</table>

13.00 – 14.30 Lunch

<table>
<thead>
<tr>
<th>Natural Product Chemistry</th>
<th>Chair: Knut Ohlsen</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>14.30</strong> Tobias Gulder</td>
<td></td>
</tr>
<tr>
<td>Exploring and Exploiting Bacterial Natural Product Biosynthesis</td>
<td></td>
</tr>
<tr>
<td><strong>15.05</strong> Peter Seeberger</td>
<td></td>
</tr>
<tr>
<td>Preventing and Curing Infectious Diseases: Carbohydrate Vaccines and Continuous Flow Synthesis</td>
<td></td>
</tr>
<tr>
<td><strong>15.40</strong> Short Talk: Usama Abdelmohsen</td>
<td></td>
</tr>
<tr>
<td>New Bioactive Natural Products Discovery from Marine Sponge-Associated Actinomycetes</td>
<td></td>
</tr>
</tbody>
</table>

15.55 – 16.15 Coffee Break

<table>
<thead>
<tr>
<th>Pathogen Biology / Drug Discovery</th>
<th>Chair: Gerhard Bringmann</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>16.15</strong> Alan Fairlamb</td>
<td></td>
</tr>
<tr>
<td>Drug Discovery for neglected diseases – successes failures and lessons learned</td>
<td></td>
</tr>
<tr>
<td><strong>16.50</strong> Simon Croft</td>
<td></td>
</tr>
<tr>
<td>Challenges and opportunities for the development of new treatments for leishmaniasis</td>
<td></td>
</tr>
<tr>
<td><strong>17.25</strong> Short Talk: Alena Zikova</td>
<td></td>
</tr>
<tr>
<td>Designing an effective inhibitor of Trypanosoma brucei F1-ATPase</td>
<td></td>
</tr>
</tbody>
</table>

Evening Poster Session
**Thursday, November 21**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.00</td>
<td>Pathogen Biology I</td>
<td>Gerald Späth: <em>Anti-leishmanial drug development efforts at Institut Pasteur: From basic parasite biology to drug target identification and validation</em></td>
</tr>
<tr>
<td>9.35</td>
<td></td>
<td>Ger van Zandbergen: <em>Leishmania interaction with human macrophages and T cells</em></td>
</tr>
<tr>
<td>10.10</td>
<td></td>
<td>Iris Gonzalez-Leal: <em>Cathepsin-deficient dendritic cells present alterations in maturation and cytokine production in response to Leishmania major infection</em></td>
</tr>
<tr>
<td>10.25</td>
<td></td>
<td>Coffee Break</td>
</tr>
<tr>
<td>10.45</td>
<td>Pathogen Biology II</td>
<td>Steffen Rupp: <em>A screening assay based on host-pathogen interaction models identifies a set of novel antifungal benzimidazole derivatives and their Target</em></td>
</tr>
<tr>
<td>11.20</td>
<td></td>
<td>Axel Brakhage: <em>Pathobiology of Aspergillus fumigatus and the discovery of novel compounds</em></td>
</tr>
<tr>
<td>11.55</td>
<td></td>
<td>Lunch</td>
</tr>
<tr>
<td>13.25</td>
<td>Structure Based Medicinal Chemistry</td>
<td>François Diederich: <em>Structure-Based Design in the Generation and Optimization of New Lead Compounds Against Infectious Diseases</em></td>
</tr>
<tr>
<td>14.00</td>
<td></td>
<td>Alexander Titz: <em>Discovery of two classes of potent glycomimetic inhibitors of Pseudomonas aeruginosa LecB with distinct binding modes</em></td>
</tr>
<tr>
<td>14.15</td>
<td></td>
<td>Maurizio Botta: <em>Design, synthesis and biological evaluation of human DDX3 inhibitors with multiple antiviral activities</em></td>
</tr>
<tr>
<td>14.50</td>
<td></td>
<td>Julia Kirchebner: <em>Development of CHVB_0032 – a small molecule inhibitor of chikungunya virus</em></td>
</tr>
<tr>
<td>15.05</td>
<td></td>
<td>Coffee Break</td>
</tr>
<tr>
<td>15.25</td>
<td>Drug Development: Binding Energy and Kinetics</td>
<td>Helena Danielson: <em>From Fragments to Transition State Analogues – Drug Discovery using SPR Biosensor Technology</em></td>
</tr>
<tr>
<td>16.00</td>
<td></td>
<td>Jon Essex: <em>Protein-Ligand Binding by Free Energy Simulations: Issues, Successes and Failures</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Guided Tour</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Conference Dinner</td>
</tr>
</tbody>
</table>
### Friday, November 22

**Computer-aided Drug Design**  
Chair: Bernd Engels

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.00</td>
<td>Samuel de Visser</td>
<td>Computational Bioengineering of Non-heme iron dioxygenases: How to change the enantioselectivity of the enzyme</td>
</tr>
<tr>
<td>9.35</td>
<td>Xavier Barril</td>
<td>Modulation of chemotactic responses with protein-protein interfacial binders discovered through structure-based methods</td>
</tr>
<tr>
<td>10.10</td>
<td>Wook Lee</td>
<td>The mechanism of how KasA is activated by its own substrate</td>
</tr>
</tbody>
</table>

**Natural Product Chemistry**  
Chair: Tanja Schirmeister

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.45</td>
<td>Hans-Dieter Arndt</td>
<td>Peptide natural products and small molecules as tools in Chemical Biology</td>
</tr>
<tr>
<td>11.20</td>
<td>Jeroen Dickschat</td>
<td>Natural Products from Microorganisms – Structure Elucidation, Synthesis and Biosynthesis</td>
</tr>
<tr>
<td>11.55</td>
<td>Michael Zender</td>
<td>Discovery and Biophysical Characterization of 2-Amino-Oxadiazoles as Novel Antagonists of PqsR, an Important Regulator of Pseudomonas aeruginosa Virulence</td>
</tr>
</tbody>
</table>

12.10 Poster Prize

12.25 Closing Remarks: Ulrike Holzgrabe